Navigation Links
Medicare Establishes Reimbursement Coverage for Vermillion's OVA1(TM) Test
Date:3/12/2010

lignancy in women with ovarian mass for whom surgery is planned.

OVA1 is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. It is an aid to further assess the likelihood that malignancy is present when the physician's independent clinical and radiological evaluation does not indicate malignancy. The test should not be used without an independent clinical/radiological evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use of the OVA1 Test carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. QMed, Inc. Reports July Medicare SNP Enrollments
2. Change in Medicare and Medicaid Legislation Creates Market for Antimicrobial Coatings In the U.S.
3. House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels
4. Medicare Coverage Recommended for In-Home Sleep Testing
5. MedicareCRM(TM) to Speak at IIR Medicare Advantage Congress
6. STAAR Surgicals Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services
7. Medicare Approves in Home Sleep Apnea Testing
8. Medtronic Unit to Pay $75 Million to Settle Whistleblower Medicare Fraud Case
9. Medicare Exemplary Provider Accreditation Awarded to Regenesis Biomedical
10. Arcadian Health Plan Addresses Medicare Doctor Payment Cuts
11. Netsmart Technologies Web Seminar Helps Behavioral Health Organizations Understand Electronic Prescribing and the Importance of New Medicare-Related E-Prescribing Legislation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... ... a field clinical study of its canine osteoarthritis stem cell product, currently under ... (Kansas City, KS) and will be marketed in the US by Aratana. This ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's ... designed for continuous operation up to 1500 bar. The sanitary design gauge of ... preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution for ...
(Date:7/29/2015)... 29, 2015 US-Australian drug discovery company, Novogen ... it is committed to progressing its ground-breaking technology platforms ... and to ensure the Company delivers the best value ... Iain Ross , said the Company currently had an ... programs, discovery programs and academic partnerships and initiatives, and ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, ... Research Council Institute for Biodiagnostics (NRC-IBD) Atlantic. This ... track the effect of IVT,s DepoVax(TM) technology on ... potential to deliver extremely sensitive MRI analysis, down ...
... NANTONG CITY, China, May 20 Sinobiopharma, Inc. (OTC Bulletin ... an update on the Company,s progress to date this year ... of 2009.Financial Highlights: , , , ... Company,s total revenue increased to RMB 4.60 million (US $0.68 ...
... LAMBERTVILLE, N.J. , May 20 Health Strategies ... pharmaceutical and biotechnology industries, analyzed trends shaping future sales ... these new models at the 38th Annual Society of ... in Chicago.In an address titled "Sales Force of the ...
Cached Biology Technology:ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin 2Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009 2Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009 3Health Strategies Group Forecasts Emerging Trends in Future Sales Force Models at the SPBT 2009 Conference 2Health Strategies Group Forecasts Emerging Trends in Future Sales Force Models at the SPBT 2009 Conference 3
(Date:7/23/2015)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... second quarter ended June 30, 2015.  Revenue ... decrease of 33% compared to $6.8 million in the same ... 2015 was $0.3 million, or $0.01 per diluted share, which ... the same period a year ago.  Lower ...
(Date:7/21/2015)... 21, 2015 Today, ZTE announced its Android ... well as expected revenues in 2015 that relate to sales of ... guidance of approximately 2,200 MSEK for 2015. Jörgen Lantto, ... smartphone manufacturer in China and we are ... 5 for Axon , its ...
(Date:7/21/2015)... Passwords have proven futile for securing ... U.S. Office of Personnel Management breach. Biometric authentication ... but developers and end-users are concerned about how ... Biometrics-as-a-Service provider HYPR Corp. announced today the general ... party integration. A video overview ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... tragedy of chronic alcoholism there is heartbreak in the ... heart and that mitochondria, the cellular energy factories, are ... precise mechanism. Now new experiments led by a ... State Department of Health in Albany, and Thomas Jefferson ...
... indicate that tree cover in urban areas of the United States ... year, according to a U.S. Forest Service study published recently in ... 17 of the 20 cities analyzed in the study declined while ... rooftops. Land that lost trees was for the most part converted ...
... Journalists may now register and reserve housing ... the "World Series of Science." One of the largest scientific ... (ACS) 243rd National Meeting & Exposition. More than 14,000 scientists ... held March 25-29, 2012, in San Diego, Calif., at the ...
Cached Biology News:A change of heart 2Study: Nation's urban forests losing ground 2Study: Nation's urban forests losing ground 3
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor...
Recombinant Rat CINC-2 beta, CF...
SHEEP ANTI FLECAINIDE...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: